AAP
AUPH icon

Ardsley Advisory Partners’s Aurinia Pharmaceuticals AUPH Stock Holding History

Ardsley Advisory Partners’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-225,000
Closed -$2.92M – 138
2021
Q1 		$2.92M Sell
225,000
-182,000
-45% -$2.64M 0.36% 42
2020
Q4 		$5.63M Buy
407,000
+27,500
+7% +$400K 0.92% 31
2020
Q3 		$5.59M Buy
+379,500
New +$5.5M 1.08% 28

Other funds holding AUPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Ardsley Advisory Partners's AUPH Position: Q2 2021 in Review

Ardsley Advisory Partners sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2021, closing a stake of 225,000 shares — an estimated $2.92M sold.

Ardsley Advisory Partners first reported a position in AUPH in Q3 2020 and held it in 3 quarters. The position peaked at $5.63M in Q4 2020. 167 funds tracked by Wall St. Rank hold AUPH as of Q2 2021.

  • Ardsley Advisory Partners reported no remaining Aurinia Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Ardsley Advisory Partners sold 225,000 Aurinia Pharmaceuticals shares in Q2 2021, an estimated $2.92M.
  • Ardsley Advisory Partners first reported a position in Aurinia Pharmaceuticals in Q3 2020 and held it in 3 quarters.
  • Ardsley Advisory Partners's Aurinia Pharmaceuticals position peaked at $5.63M in Q4 2020.
  • 167 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2021.

Based on Ardsley Advisory Partners's 13F filing for Q2 2021, filed 16 Aug 2021.